Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 9/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133989 | 0.89 | QPCT (0.50) | QPCTNAMPTROCK2RAB9ANPC1 | |
| SCHEMBL2995008 | 0.76 | NAMPT (0.53) | QPCTNAMPTROCK2ROCK1 | |
| SCHEMBL2995010 | 0.76 | NAMPT (0.53) | QPCTNAMPTROCK2ROCK1 | |
| SCHEMBL27548487 | 0.76 | NPC1 (0.55) | QPCTNAMPTROCK2ROCK1RAB9A | |
| SCHEMBL13373422 | 0.74 | NAMPT (0.81) | QPCTNAMPTROCK2RAB9ATP53 | |
| SCHEMBL3634863 | 0.74 | QPCT (0.84) | QPCTNAMPTROCK1RAB9ANPC1 | |
| SCHEMBL26190497 | 0.73 | ROCK2 (0.53) | QPCTNAMPTROCK2ROCK1RAB9A | |
| SCHEMBL9960184 | 0.72 | NAMPT (0.62) | QPCTNAMPTROCK2RAB9AMAPT | |
| SCHEMBL13373434 | 0.72 | QPCT (0.53) | QPCTNAMPTRAB9ATP53MAPT | |
| SCHEMBL5265934 | 0.70 | NAMPT (0.51) | QPCTNAMPTROCK2RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885NAMPT 1137/4885ROCK2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.